PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

References

• Suurmeijer AJH, De Bruijn D, Geurts van Kessel AH, Miettinen MM. Synovial sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F, editors. WHO classification of tumours of soft tissue and bone 4th. Lyon, France: IARC Press; 2013. 213–215. doi:
   Google Scholar
• Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014;3:1404–1415. doi:10.1002/cam4.288.
   PubMed Web of Science ®Google Scholar
• Wang S, Song R, Sun T, Hou B, Hong G, Mallampati S, Sun H, Zhou X, Zhou C, Zhang H, et al. Survival changes in patients with synovial sarcoma, 1983–2012. J Cancer. 2017;8:1759–1768. doi:10.7150/jca.17349.
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology, and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–3547. doi:10.1002/cncr.24424.
   PubMed Web of Science ®Google Scholar
• Vlenterie M, Jones RL, van der Graaf WT. Synovial sarcoma diagnosis and management in the era of targeted therapies. Curr Opin Oncol. 2015;27:316–322. doi:10.1097/CCO.0000000000000198.
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, Emori M, Nagoya S, Kaya M, Torigoe T, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese musculoskeletal oncology group. Cancer Sci. 2012;103:1625–1630. doi:10.1111/j.1349-7006.2012.02370.x.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–1027. doi:10.1158/1078-0432.CCR-14-2708.
   PubMed Web of Science ®Google Scholar
• Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, et al. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017;7:11. doi:10.1186/s13569-017-0077-3.
   PubMed Web of Science ®Google Scholar
• Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res. 2011;17:5615–5625. doi:10.1158/1078-0432.CCR-11-1066.
   PubMed Web of Science ®Google Scholar
• Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 2017;61:130–139. doi:10.1016/j.humpath.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old LJ. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001;94:252–256. doi:
   PubMed Web of Science ®Google Scholar
• Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22:1234–1242. doi:10.1158/1078-0432.CCR-15-2071.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199–208. doi:
   PubMed Web of Science ®Google Scholar
• Orlando D, Miele E, de Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, et al. Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma. Cancer Res. 2018;78:3337–3349. doi:10.1158/0008-5472.CAN-17-3140.
   PubMed Web of Science ®Google Scholar
• Szuhai K, Ijszenga M, De Jong D, Karseladze A, Tanke HJ, Hogendoorn PCW. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. ClinCancer Res. 2009;15:2259–2268. doi: 1078-0432.CCR-08-2184 [pii];10.1158/1078-0432.CCR-08-2184 [doi]
   Google Scholar
• Gezgin G, Luk SJ, Cao J, Dogrusoz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, et al. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol. 2017;135:541–549. doi:10.1001/jamaophthalmol.2017.0729.
   PubMed Web of Science ®Google Scholar
• Fernandez JE, Concha A, Aranega A, Ruiz-Cabello F, Cabrera T, Garrido F. HLA class I and II expression in rhabdomyosarcomas. Immunobiology. 1991;182:440–448. doi:10.1016/S0171-2985(11)80208-1.
   PubMed Web of Science ®Google Scholar
• Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, et al. Synovial sarcoma is a stem cell malignancy. Stem Cells. 2010;28:1119–1131. doi:10.1002/stem.452.
   PubMed Web of Science ®Google Scholar
• Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, van Beelen E, van Boven H, Haas RL, Italiano A, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncoimmunology. 2018;7:e1386828. doi:10.1080/2162402X.2017.1386828.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Kawai A, Leung DH, Lonardo F, Woodruff JM, Healey JH, Ladanyi M. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol. 2000;9:1–8. doi:
   PubMedGoogle Scholar
• Fisher C. Synovial sarcoma: ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol. 1986;17:996–1008. doi:
   PubMed Web of Science ®Google Scholar
• Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, Meltzer PS. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol. 2002;161:1587–1595. doi:10.1016/S0002-9440(10)64437-9.
   PubMed Web of Science ®Google Scholar
• Sundara YT, Kostine M, Cleven AH, Bovee JV, Schilham MW, Cleton-Jansen AM. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119–128. doi:10.1007/s00262-016-1925-3.
   PubMed Web of Science ®Google Scholar
• Kallio MA, Tuimala JT, Hupponen T, Klemela P, Gentile M, Scheinin I, Koski M, Kaki J, Korpelainen EI. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genomics. 2011;12:507. doi:10.1186/1471-2164-12-507.
   PubMed Web of Science ®Google Scholar
• Szuhai K, Ijszenga M, Tanke HJ, Rosenberg C, Hogendoorn PC. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genet Cytogenet. 2006;166:173–179. doi:10.1016/j.cancergencyto.2005.11.006.
   PubMedGoogle Scholar
• Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, et al. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 2002;160:849–859. doi:10.1016/S0002-9440(10)64908-5.
   PubMed Web of Science ®Google Scholar
• Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, De Alava E, Myklebost O, Kresse SH, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 2010;49:40–51. doi:10.1002/gcc.20717.
   PubMed Web of Science ®Google Scholar
• Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, Beppu Y. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 2004;204:105–113. doi:
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, Willemze R, Falkenburg JH. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109:235–243. doi:10.1182/blood-2006-03-013318.
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, de Paus RA, Lurvink EG, Koning F, Mulder A, Willemze R, van Rood JJ, Falkenburg JH. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A. 2001;98:6806–6811. doi:10.1073/pnas.111162298.
   PubMed Web of Science ®Google Scholar
• Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57:197–206. doi:10.1007/s00262-007-0362-8.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–213. doi:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Gorter A, Prins F, van Diepen M, Punt S, van der Burg SH. The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med. 2015;13:295. doi:10.1186/s12967-015-0664-0.
   PubMed Web of Science ®Google Scholar